Recently, the certification agency of Jiangsu Province officially announced the first batch of high-tech enterprises to be recognized and reported in 2025, and Xinqing Medical (Suzhou) Co., Ltd. was successfully selected. As a national authoritative qualification certification for technology innovation enterprises in China, the award of the title of high-tech enterprise is a high recognition of Xinqing Medical's comprehensive strength in independent research and development of core technologies, industrialization of scientific and technological achievements, and empowerment of the domestic market. This recognition, combined with the company's achievement of being selected as a "Potential Unicorn Enterprise in Jiangsu Province" for five consecutive years, marks its breakthrough and innovative practice in the localization of multi organ life support. It has received dual recognition from the national and local governments and has become a benchmark enterprise for promoting high-level technological self-reliance and self-improvement of medical devices in China.
Xinqing Medical was selected as a high-tech enterprise
The core of identifying high-tech enterprises focuses on key dimensions such as R&D investment intensity, core intellectual property rights, and the ability to transform scientific and technological achievements. It is an important yardstick for measuring the technological innovation strength of enterprises. Since its establishment, Xinqing Medical has always taken "solving domestic clinical pain points, breaking foreign technological barriers, and achieving independent controllability and import substitution of key technologies" as its core mission. Relying on the perfect medical industry ecology and innovative resources in Jiangsu Province, it practices the development model of "medical engineering integration and joint research and development" and fully conforms to the recognition standards of high-tech enterprises. Founder Dr. Xu Boling, with her top-notch educational background at home and abroad and over 20 years of deep experience in the field of artificial heart, led the team to build an interdisciplinary innovation platform, deeply integrating international cutting-edge technology concepts with domestic clinical needs, and gathering global smart services for Chinese innovation. In terms of intellectual property layout, enterprises have applied for over 400 patents, with core patents focusing on domestic technological shortcomings. In the past two years, most of the newly added patents have served the iteration and industrialization of domestic products. At the same time, the international patent layout completed in countries such as the United States and Europe has become an extension of domestic technological strength. In addition, the enterprise undertakes special funding support projects for the transformation of scientific and technological achievements in Jiangsu Province, establishes stable cooperation with multiple clinical centers in China, and forms a virtuous cycle of "research and development clinical transformation", with the efficiency of scientific and technological achievement transformation ranking among the top in the industry.
Behind this high-tech enterprise recognition is the solid industrialization achievements of Xinqing Medical in the field of multi organ life support in China: MoyoAssist® Approved for listing by the National Medical Products Administration (NMPA), breaking the monopoly of foreign technology and incorporating it into medical insurance in multiple provinces and cities, allowing domestically produced technology to benefit more patients; The new generation portable ECMO system BreathMo® Received special funding support for the transformation of scientific and technological achievements in Jiangsu Province, served as an emergency support provider for the Hangzhou Asian Games, and adapted to various domestic emergency scenarios; Minimally invasive artificial heart NyokAssist® Through NMPA innovation review, clinical validation has been completed domestically, and its technical strength has been internationally recognized at the same time. These products are closely related to domestic demand from research and development to implementation, and have built a localized life support system covering multiple scenarios, demonstrating the core value of high-tech enterprises' "technological innovation serving people's livelihood".
It is worth mentioning that the domestic innovation achievements of Xinqing Medical have also received attention and recognition from the global industry - the company has been nominated for the "Best Start up Enterprise" award at the Galen Awards, NyokAssist ® The clinical trial data was released at the TCT 2025 International Conference and received high praise. These international echoes are not independent layouts, but natural manifestations of domestic independent innovation technology reaching the global advanced level, further confirming the technological hard power of China's high-tech enterprises.
This selection as a high-tech enterprise not only brings multiple dividends such as policy support, brand trust enhancement, and talent aggregation to Xinqing Medical, but also strengthens the company's responsibility to deeply cultivate the domestic market and promote localization substitution. In the future, Xinqing Medical will take this national level certification as an important opportunity to continue increasing domestic research and development investment, focusing on tackling the "bottleneck" technology in the field of multi organ life support, further improving the domestic product matrix, accelerating the national medical insurance coverage and clinical popularization of core products, and enabling independently innovated advanced medical technologies to benefit a wider range of Chinese patients.